Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial

Joly, 2004, Chemotherapy for patients with hormone-refractory prostate cancer, Ann Oncol, 15, 1582, 10.1093/annonc/mdh445 Tannock, 1996, Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points, J Clin Oncol, 14, 1756, 10.1200/JCO.1996.14.6.1756 Kantoff, 1999, Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 Study, J Clin Oncol, 17, 2506, 10.1200/JCO.1999.17.8.2506 Osoba, 1999, Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone, J Clin Oncol, 17, 1654, 10.1200/JCO.1999.17.6.1654 Tannock, 2004, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, N Engl J Med, 351, 1502, 10.1056/NEJMoa040720 Petrylak, 2004, Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer, N Engl J Med, 351, 1513, 10.1056/NEJMoa041318 Roth, 1993, Taxol in advanced, hormone-refractory carcinoma of the prostate, Cancer, 72, 2457, 10.1002/1097-0142(19931015)72:8<2457::AID-CNCR2820720825>3.0.CO;2-Z Esteban, 2003, Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy, Ann Oncol, 14, 1640, 10.1093/annonc/mdg456 Seidman, 2004, CALGB 9840: Phase III study of weekly paclitaxel via 1-hour infusion versus standard 3h infusion every third week in the treatment of metastatic breast cancer, with trastuzumab for HER2 positive MBC and randomized for T in HER2 normal MBC, J Clin Oncol, 22, 512, 10.1200/jco.2004.22.14_suppl.512 Trivedi, 2000, Weekly 1-hour infusion of paclitaxel, Cancer, 89, 431, 10.1002/1097-0142(20000715)89:2<431::AID-CNCR31>3.0.CO;2-B Huan, 1994, 5-fluorouracil and high dose folinic acid in hormone-refractory metastatic prostate cancer: A phase II study, Ann Oncol, 5, 644, 10.1093/oxfordjournals.annonc.a058938 1992, Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate, J Clin Oncol, 10, 896, 10.1200/JCO.1992.10.6.896 Ardalan, 1991, A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma, J Clin Oncol, 9, 625, 10.1200/JCO.1991.9.4.625 Lin, 2001, A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer, Anticancer Res, 21, 1385 Droz, 2003, Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients, Ann Oncol, 14, 1291, 10.1093/annonc/mdg342 Pu, 2001, Cross-resistance and combined cytotoxic effects of paclitaxel and cisplatin in bladder cancer cells, J Urol, 166, 2082, 10.1016/S0022-5347(05)66298-2 Chou, 1984, Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors, Adv Enzyme Regul, 22, 27, 10.1016/0065-2571(84)90007-4 Bubley, 1999, Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group, J Clin Oncol, 17, 3461, 10.1200/JCO.1999.17.11.3461 Miller, 1981, Reporting results of cancer treatment, Cancer, 47, 207, 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 Melzack, 1975, The McGill Pain Questionnaire: Major properties and scoring methods, Pain, 1, 277, 10.1016/0304-3959(75)90044-5 Saad, 2002, A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma, J Natl Cancer Inst, 94, 1458, 10.1093/jnci/94.19.1458 Shuster, 1991, Median follow-up in clinical trials, J Clin Oncol, 9, 191, 10.1200/JCO.1991.9.1.191 Verbel, 2003, Estimating survival benefit in castrate metastatic prostate cancer: Decision making in proceeding to a definitive phase III trial, Urology, 61, 142, 10.1016/S0090-4295(02)02097-6 Holmes, 1996, Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer, J Clin Oncol, 14, 2713, 10.1200/JCO.1996.14.10.2713 Grem, 1999, Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells, Biochem Pharmacol, 58, 477, 10.1016/S0006-2952(99)00099-4 Smith, 1999, Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer, J Clin Oncol, 17, 1664, 10.1200/JCO.1999.17.6.1664 Kelly, 2001, Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer, J Clin Oncol, 19, 44, 10.1200/JCO.2001.19.1.44 Savarese, 2001, Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780, J Clin Oncol, 19, 2509, 10.1200/JCO.2001.19.9.2509 Oh, 2003, A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813, Cancer, 98, 2592, 10.1002/cncr.11829 Oudard, 2005, Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer, J Clin Oncol, 23, 3343, 10.1200/JCO.2005.12.187